{"product_id":"ipamorelin-pen","title":"Ipamorelin | 15 mg pen","description":"\u003cp\u003e\u003cstrong\u003eIpamorelin\u003c\/strong\u003e is a peptide positioned for controlled research settings where \u003cstrong\u003eghrelin receptor (GHS-R1a) signaling\u003c\/strong\u003e is being studied in relation to \u003cstrong\u003epulsatile growth hormone dynamics, IGF-1 axis outputs, and recovery-linked endocrine endpoints\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSupports\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003ePhysiologic GH pulse amplitude and timing endpoints (protocol-dependent)\u003c\/li\u003e\n\u003cli\u003eDownstream IGF-1\/IGFBP marker tracking in endocrine study designs\u003c\/li\u003e\n\u003cli\u003eSleep-associated GH rhythm investigations (circadian alignment measures)\u003c\/li\u003e\n\u003cli\u003eMetabolic signaling readouts connected to GH\/ghrelin pathways (model-dependent)\u003c\/li\u003e\n\u003cli\u003eSelective secretagogue profiling vs broader GHRPs (ACTH\/cortisol\/prolactin panels)\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003ch2\u003eDescription\u003c\/h2\u003e\n\u003cp\u003eIpamorelin (development code NNC 26-0161) is a selective growth hormone secretagogue studied as a ghrelin receptor (GHS-R1a) agonist that promotes endogenous, pulsatile growth hormone release. In research literature, it is frequently discussed for a comparatively targeted GH-focused profile relative to earlier growth hormone releasing peptides, with endocrine-panel monitoring used to characterize selectivity.\u003c\/p\u003e\n\u003cp\u003eIn controlled models, ipamorelin is used to probe hypothalamic–pituitary signaling that shapes GH pulsatility, and to map downstream endocrine outputs such as IGF-1 axis markers. Study designs commonly quantify GH pulse kinetics, time-to-peak effects, and downstream biomarker shifts, while also tracking off-axis hormone changes to evaluate signaling specificity.\u003c\/p\u003e\n\u003cp\u003eIpamorelin is positioned strictly for research use, where outcomes should be interpreted within predefined endpoints and controlled experimental protocols.\u003c\/p\u003e\n\u003ch2\u003eClinical Status\u003c\/h2\u003e\n\u003cp\u003eIpamorelin has been studied in preclinical models and exploratory human research contexts evaluating GH secretagogue pharmacology, kinetics, and endocrine selectivity. It is not described as having regulatory approval for therapeutic use in the provided raw text.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence type:\u003c\/strong\u003e\u003cbr\u003e\u003cspan\u003eHuman RCT ▣ | Observational ▣ | Animal ✔ | In vitro ✔\u003c\/span\u003e | Regulatory approval ☐\u003c\/p\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eIpamorelin is studied as a GHS-R1a agonist that stimulates endogenous GH release through hypothalamic–pituitary pathways. GHS-R1a activation is commonly linked to intracellular signaling that includes phospholipase C\/IP3-mediated calcium mobilization and downstream kinase activity, supporting GH exocytosis in somatotroph systems and related neuroendocrine signaling endpoints.\u003c\/p\u003e\n\u003cp\u003eCompared with broader-acting GHRPs, ipamorelin is often evaluated for a more GH-selective endocrine signature, assessed by measuring GH pulse characteristics alongside panels that may include ACTH\/cortisol and prolactin, depending on protocol. Downstream effects are typically studied via IGF-1 axis outputs and model-specific recovery or metabolic biomarkers.\u003c\/p\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eSupports natural growth hormone pulses:\u003c\/b\u003e\u003cbr\u003eIpamorelin works by stimulating your body’s own growth hormone release rather than replacing it with synthetic GH. This means the pituitary gland remains active and responsive. Growth hormone is normally released in pulses throughout the day, especially during deep sleep. By encouraging this natural rhythm, Ipamorelin supports a more physiological hormone pattern. This approach helps maintain endocrine balance instead of bypassing regulatory systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEncourages recovery through endogenous pathways:\u003c\/b\u003e\u003cbr\u003eGrowth hormone plays an important role in tissue repair, muscle recovery, and protein synthesis. By stimulating natural GH release, Ipamorelin indirectly supports the body’s recovery signaling network. This includes downstream IGF-1 production, which is involved in structural repair processes. Instead of forcing supraphysiological levels, it works within the body’s own hormone framework.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMaintains hormonal feedback integrity:\u003c\/b\u003e\u003cbr\u003eOne of the key differences between stimulating GH and injecting it directly is preservation of feedback loops. Ipamorelin activates the pituitary while keeping hypothalamic regulation intact. This means the body can still modulate output based on its needs. Maintaining this feedback system is important in research focused on long-term endocrine stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSelective stimulation with minimal stress-hormone impact:\u003c\/b\u003e\u003cbr\u003eEarlier growth hormone releasing peptides were associated with increased cortisol or prolactin levels. Ipamorelin was designed to be more selective at the ghrelin receptor. This selectivity allows GH stimulation without significant activation of stress-related hormone pathways. The result is a cleaner hormonal profile in experimental settings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSupports sleep-associated hormone cycles:\u003c\/b\u003e\u003cbr\u003eGrowth hormone release naturally peaks during deep sleep stages. Ipamorelin has been studied for its ability to enhance physiologic nighttime GH pulses. Since sleep quality and recovery are closely linked to hormone rhythms, this timing alignment is relevant in recovery-focused research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEngages downstream IGF-1 signaling:\u003c\/b\u003e\u003cbr\u003eWhen growth hormone increases, the liver produces insulin-like growth factor 1 (IGF-1). IGF-1 is associated with muscle repair, cellular growth, and metabolic signaling. By stimulating GH first, Ipamorelin activates this secondary pathway in a stepwise, physiological manner. This layered response mimics the body’s natural hormone cascade.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eExplored in age-related hormone decline models:\u003c\/b\u003e\u003cbr\u003eNatural growth hormone production decreases over time. Ipamorelin has been evaluated in research examining reduced GH levels associated with aging. Rather than introducing external hormones, it encourages the body to resume endogenous production patterns. This makes it relevant in studies of endocrine aging biology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSupports structured, controlled hormone research:\u003c\/b\u003e\u003cbr\u003eProvided in a stabilized pre-mixed injection pen for SubQ administration, Ipamorelin allows consistent exposure in controlled research protocols. Subcutaneous delivery enables predictable absorption. Each unit is freshly prepared and intended strictly for laboratory use only.\u003c\/li\u003e\n\u003cli\u003e\u003cbr\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eResearch Data\u003c\/h2\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\" style=\"width: 100%; border-collapse: collapse;\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStudy\/model\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReported effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelective GH secretagogue characterization (preclinical and translational pharmacology)\u003c\/td\u003e\n\u003ctd\u003eGH release selectivity described with reduced off-axis endocrine effects compared with earlier GHRPs (model-dependent)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRat pharmacokinetics and route-of-administration studies\u003c\/td\u003e\n\u003ctd\u003ePK parameters reported; comparative clearance differences described versus other GHRPs in controlled studies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGHS-R1a signaling in somatotroph systems (cell\/biochemical models)\u003c\/td\u003e\n\u003ctd\u003eCalcium-linked signaling and kinase pathway activation described as mechanistic components supporting GH release\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth hormone secretagogue review literature\u003c\/td\u003e\n\u003ctd\u003eMechanism, history, and clinical-trial progression of GHS classes summarized; ipamorelin discussed within the category\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePostoperative ileus model (rodent)\u003c\/td\u003e\n\u003ctd\u003eGhrelin-mimetic effects on gastrointestinal motility endpoints investigated with ipamorelin in a controlled model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBone-related endpoints under glucocorticoid exposure (rat model)\u003c\/td\u003e\n\u003ctd\u003eBone formation and turnover-related outcomes explored with ipamorelin in a preclinical context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComparative GHRP\/GHS mechanistic work\u003c\/td\u003e\n\u003ctd\u003eGHRP class activity examined as ghrelin receptor agonism, supporting comparative endocrine profiling designs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystems-level ghrelin\/GHS integration reviews\u003c\/td\u003e\n\u003ctd\u003eGhrelin system integration and endocrine coordination described, providing context for GHS-R1a agonist study designs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eStack Suggestions\u003c\/h2\u003e\n\u003cp\u003eIn extended experimental designs, Ipamorelin is sometimes paired with:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCJC-1295 (No-DAC) → dual-pathway GH pulse studies (GHRH receptor + GHS-R1a)\u003c\/li\u003e\n\u003cli\u003eGHRP-2 → comparative secretagogue profiling (pulse amplitude\/selectivity endpoints)\u003c\/li\u003e\n\u003cli\u003eNAD+ → energy-state and recovery biomarker tracking alongside endocrine endpoints\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eStacks discussed are for experimental design only, not safety\/efficacy guidance.\u003c\/p\u003e\n\u003ch2\u003ePossible Side Effects\u003c\/h2\u003e\n\u003cp\u003eIf ipamorelin is used in experimental systems, observed effects may include transient injection-site reactions (redness, irritation), short-lived headache or flushing, and fluid-balance changes that can occur when GH signaling is experimentally increased. Because ghrelin receptor agonism can interface with broader neuroendocrine networks, protocols commonly include endocrine-panel monitoring (e.g., cortisol\/prolactin where relevant), sleep-related observations, and glucose-related biomarkers in susceptible models. Effects are model- and exposure-dependent and should be interpreted only within controlled study frameworks.\u003c\/p\u003e\n\u003ch2\u003eScientific References\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9849822\/\"\u003eIpamorelin, the first selective growth hormone secretagogue\u003c\/a\u003e — Animal\/In vitro\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9879640\/\"\u003ePharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption\u003c\/a\u003e — Animal\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC1751558\/\"\u003eRegulation of ERK1\/2 activity by ghrelin-activated growth hormone secretagogue receptor 1a\u003c\/a\u003e — In vitro\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/rco2.9\"\u003eGrowth hormone secretagogues: history, mechanism of action, and clinical development\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2010\/879503\"\u003eIntegrating growth hormone secretagogues into the ghrelin system\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0022356524384538\"\u003eEfficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus\u003c\/a\u003e — Animal\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/link.springer.com\/article\/10.1385\/ENDO%3A14%3A1%3A133\"\u003eDo growth hormone-releasing peptides act as ghrelin receptor agonists?\u003c\/a\u003e — Review\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/go.drugbank.com\/drugs\/DB12370\"\u003eIpamorelin: Uses, Interactions, Mechanism of Action\u003c\/a\u003e — Reference database\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/downloads.regulations.gov\/FDA-2015-N-3534-0283\/attachment_5.pdf\"\u003eIpamorelin acetate: compiled pharmacology\/toxicology dossier excerpt (regulatory submission document)\u003c\/a\u003e — Regulatory\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"https:\/\/www.researchgate.net\/publication\/11621591_The_growth_hormone_secretagogue_ipamorelin_counteracts_glucocorticoid-induced_decrease_in_bone_formation_of_adult_rats\"\u003eThe growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats\u003c\/a\u003e — Animal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCautions\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.\u003c\/li\u003e\n\u003cli\u003eIf you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.\u003c\/li\u003e\n\u003cli\u003eDiscontinue use if sensitivity occurs.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Peptoora","offers":[{"title":"15 mg","offer_id":61559774970186,"sku":"PE-GR-PEN-006","price":399.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/Ipamorelin10mg_c56ed082-fe72-41c6-a1ee-a6f32c682367.png?v=1775839930","url":"https:\/\/peptoora.com\/fr\/products\/ipamorelin-pen","provider":"Peptoora LTD","version":"1.0","type":"link"}